Anthony Quaranta, MD
Pulmonary Disease · Norfolk, VANPI 1205801685
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.2%), food and beverage and education — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 80.5% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $921, more than ten times the $24 reported in 2020. That places this record below the midpoint for pulmonary disease clinicians in VA, where the typical reported total is $1,962.
Across 7 payments — averaging $163.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$921
- Harmony Biosciences LLC$100
- Intuitive Surgical$99
- CSL Behring$24
Across 14 payments — averaging $8186.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$106K
- F. Hoffmann-la Roche AG$8K
What the payments were for
- Travel & lodging$63255%
- Food & beverage$38834%
- Education$12411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 4 | $921 |
| Harmony Biosciences LLC | 1 | $100 |
| Intuitive Surgical | 1 | $99 |
| CSL Behring | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$921
How this compares
$1,145 in reported general payments places this provider in the 40th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $20,789 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $12,563 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $10,548 |
| Spiriva RespimatTiotropium Bromide | 12 | $9,304 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 70 | $1,484 |
| Azithromycin | 19 | $99 |
| Montelukast Sodium | 13 | $57 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Norfolk
- Joshua SillNorfolk$29K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.